2024
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A. Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis. Journal Of Clinical Oncology 2024, 42: 8106-8106. DOI: 10.1200/jco.2024.42.16_suppl.8106.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaProgression-free survivalTreatment-related adverse eventsPD-L1 statusOverall survivalPD-L1Systemic therapyRetrospective analysisGrades treatment-related adverse eventsTreatment approachesCell neuroendocrine carcinomaMedian follow-upMulticenter retrospective analysisTreated with chemotherapySystemic treatment approachesChemo-regimenPlatinum-etoposideNeuroendocrine carcinomaOS outcomesLine treatmentToxicity profileClinical outcomesAdverse eventsImmunotherapyIO group
2021
“The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer.
Mougalian S, Shomsky L, Campos M, Chiang A. “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2020.39.28_suppl.205.Peer-Reviewed Original ResearchTreatment initiationMedian timeCancer CenterFirst visitNew patientsNew patient volumeSubsequent treatment initiationCommon reason patientsComprehensive cancer centerEstablishment of careStudy-Act cyclesNext-day appointmentsDays-1 yearOncologic consultationBrief anonymous surveyReasons patientsClinical reviewSubspecialty clinicsCancer carePatient satisfactionWorse outcomesBreast cancerRetrospective analysisTimely appointmentsPatients